Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting

被引：0

作者：

Ray, J. A.

Valentine, W. J.

Goodall, G.

Aagren, M.

Kotchie, R. W.

机构：

[1] IMS Hlth, Hlth Econ Dept, Basel, Switzerland

[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

[3] IMS Hlth, Hlth Econ Dept, London, England

来源：

DIABETOLOGIA | 2007年 / 50卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1033

引用

页码：S428 / S428

页数：1

共 50 条

[1] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Portugal
Silva, C.
Alves, C.
Negreiro, F.
Fonseca, M. A.
Aagren, M.
VALUE IN HEALTH, 2008, 11 (03) : A227 - A227
[2] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
DIABETOLOGIA, 2005, 48 : A334 - A334
[3] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
DIABETES, 2005, 54 : A609 - A609
[4] Economic evaluation of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting
Tucker, DM
Wittrup-Jensen, KU
Roze, S
Valentine, WJ
Palmer, AJ
DIABETES, 2005, 54 : A609 - A609
[5] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Australia: A modeling evaluation based on results from a 2-year clinical trial
Fulcher, Gregory R.
Aagren, Mark
DIABETES, 2008, 57 : A338 - A339
[6] Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/-bolus therapy for Type 1 diabetes in a UK setting. An economic evaluation based on a meta-analysis of four clinical trials
Roze, S
Palmer, AJ
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
DIABETOLOGIA, 2004, 47 : A345 - A345
[7] Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
Palmer, AJ
Roze, S
Valentine, WJ
Smith, I
Wittrup-Jensen, KU
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (11) : 1729 - 1746
[8] Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Scheilbeler, H.
Aagren, M.
Nielsen, S.
Goodall, G.
Kotchie, R.
Valentine, W. J.
VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
[9] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
DIABETOLOGIA, 2004, 47 : A344 - A344
[10] Economic evaluation of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type-1 diabetes in Germany
Palmer, AJ
Valentine, WJ
Wittrup-Jensen, KU
Roze, S
VALUE IN HEALTH, 2005, 8 (06) : A161 - A161

← 1 2 3 4 5 →